A. Rossi, A. Tomassini, P. Stratta - Vol. 10, December 2004, Issue 4
Testo Immagini Bibliografia Summary Indice
Cognitività e Dopamina: aspetti clinici nella
schizofrenia
Cognition and dopamine: clinical aspects in schizophrenia
1 Diagnostic and Statistical Manual of Mental Disorder, 4th Ed. Washington, DC: American Psychiatric Association 2000.
2 Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan metanalysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003;73:34-48.
3 Harrison PJ. The neuropathology of schizophrenia: a critical review of data and their interpretation. Brain 1999;122:593-624.
4 Stahl SM. Psicofarmacologia essenziale (II Ed.). Centro Scientifico Editore 2002.
5 Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a critical review and reconceptualization. Am J Psychiatry 1991;148:1476-86.
6 Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-15.
7 Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 1992;49:943-58.
8 Lieberman JA, Kane JM, Alvir j. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987;91:415-33.
9 Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9.
10 Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological model of schizophrenia. Brain Res Brain Res Rev 1999;29:250-64.
11 Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999;13:358-71.
12 Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia relevated by PET. Nature 1997;385:634-6.
13 Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-5.
14 Deutch AY, Clark WA, Roth RH. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 1990;521:311-5.
15 Grace T. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neurosci 1991;41:1-24.
16 Cohen JD, Servan-Schreiber D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr Bull 1993;19:85-103.
17 Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotics drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990;54:1755-60.
18 Goldman-Rakic PS, Muly EC III, Williams GV. D1 receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000;31:295-301.
19 Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995;376:572-5.
20 Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287:2020-2.
21 Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinson’s disease. Ann Neurol 2002;51:156-64.
22 Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, et al. Serotoninergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998;44:1099-117.
23 Glennon RA. Do classical hallucinogenes act as 5-HT2 agonists or antagonists? Neuropsychopharmachology 1990;3:509-17.
24 Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993;50:624-35.
25 Kahn RS, Siever LJ, Gabriel S, Amin F, Stern RG, DuMont K, et al. Serotonin function in schizophrenia: effects of meta-Chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 1992;43:1-12.
26 Breier A, Kirkpatrick B, Buchanan RW. Clozapine attenuates metachlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 1993;34:492-4.
27 Koreen A, Lieberman JA, Alvir J. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first episode schizophrenia and normal controls. Neuropsychopharmachology 1997;16:61-8.
28 Nocjar C, Roth BL, Pehek EA. Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002;111:163-76.
29 Goff DC, Coyle JT. The emerging role of glutammate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.
30 Weinberger DR. Schizophrenia and the frontal lobe. Trends Neurosci 1988;11:367-70.
31 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics schizophrenia. Biol Psychiatry 2001;50:825-44.
32 Baddeley A. Human memory. Theory practice. Massachussets 1990.
33 Goldman-Rakic PS. The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999;46:650-61.
34 Berman I,Viegner B, Merson A, Pappas D, Green AI. Differential relationship between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 1997;25:1-10.
35 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
36 Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 2000;157:1646-51.
37 Goldberg TE, Seidman LJ. Higher cortical functions in normals and in schizophrenia: a selective review. In: Steinhauer SR, Gruzelier JH, Zubin J, eds. Handbook of schizophrenia, vol. 5: Neuropsychology, Psychophysiology and Information Processing. New York: Elsevier 1991.
38 Goldberg TE, Weinberger DR. Schizophrenia, training paradigms, and Wisconsin Card Sorting Test Redux. Schizophr Res 1994;11:291-6.
39 Jaeger J, Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr Quart 1992;63:71-93.
40 Jaeger J, Berns BA, Tigner A, Douglas E. Remediation of neuropsychological deficits in psychiatric populations: rationale and methodological considerations. Psychopharmacol Bull 1992;28:367-90.
41 Lysaker P, Bell M, Beam-Goulet J. Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatr Res 1995;56:45-51.
42 Stratta P, Daneluzzo E, Prosperini PL, Bustini M, Rossi A. Different influence of age and educational level on spatial working memory and WCST in schizophrenia: a controlled study. Psychiatry Res 2001;102:39-48.
43 Green MF, Marder SR, Glynn SM , McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8.
44 Green MF. Cognitive remediation in schizophrenia: is it time yet? Am J Psychiatry 1993;150:178-87.
45 Keefe RSE. The contribution of neuropsychology to psychiatry. Am J Psychiatry 1995;152:6-15.
46 Harvey PD, Keefe RS. Studies of cognitive changes in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-84.
47 Friedman JI, Temporini H, Davis K. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-16.
48 Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:18-27.
49 Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BRE, Marcus M, et al. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of the 5-HT2 receptor and a1-adrenoreceptor antagonism. J Clin Psychopharmacol 1995;15:11-8.
50 Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
51 Seeman P. Atypical antipsychotics: mechanisms of action. Can J Psychiatry 2002;47:27-38.
52 Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83.
53 Friedman JH, Factor S. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000;15:201-11.
54 Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. TIPS 1998;19:136-40.
55 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
56 Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 1999;174(Suppl 38):44-51.
57 Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and favourable side effects. J Psychopharmacol 2004;18:375-83.
58 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
59 Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
60 Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
61 Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
62 Cornblatt B, Kern RS, Carson WA, Ali MW, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Int J Neuropharmacol 2002:185-186.
63 Millian MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmachol Exp Ther 2000;259:853-61.
64 Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.
65 Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002;296:692-5.